RxLabelGuardDrug Interaction API
Updated March 2026 — landscape changes ahead

Drug Interaction API Comparison 2026

The drug interaction API landscape is shifting. DrugBank's Interaction Checker retires March 25, 2026. NLM discontinued its RxNav interaction endpoint in January 2024. Enterprise vendors are raising prices. This guide compares your remaining options side-by-side so you can make an informed decision for your stack.

Whether you are building an EHR integration, a pharmacy management system, a telehealth prescribing flow, or a clinical decision support tool, choosing the right drug interaction API affects your development timeline, operating costs, clinical accuracy, and compliance posture. We break down five options across pricing, data sources, output formats, evidence citations, and integration complexity.

Try RxLabelGuard FreeView API Docs

Side-by-Side Comparison Table

Five drug interaction API options compared across 11 criteria. Data accurate as of March 2026.

Data Source

RxLabelGuard
FDA Structured Product Labeling (SPL)
DrugBank
Proprietary curated database (14,000+ drug entries)
First Databank (FDB)
Proprietary curated database (FDB MedKnowledge)
Micromedex (Merative)
Proprietary curated database (DRUGDEX)
openFDA (DIY)
FDA SPL labels (raw, unstructured text)

Pricing Model

RxLabelGuard
Self-service tiers: Free ($0/mo), Developer ($20/mo), Professional ($99/mo)
DrugBank
Enterprise licensing (contact sales for quote)
First Databank (FDB)
Enterprise licensing ($50K-$200K+/year typical)
Micromedex (Merative)
Enterprise licensing ($50K-$200K+/year typical, bundled)
openFDA (DIY)
Free (data access only; you build the infrastructure)

Free Tier

RxLabelGuard
Yes — 50 requests/month, 1 API key, no credit card required
DrugBank
Interaction Checker retiring March 2026; no free API tier
First Databank (FDB)
No
Micromedex (Merative)
No
openFDA (DIY)
Yes — 240 req/min with API key (raw data only)

Setup Time

RxLabelGuard
Self-service; minutes to first API call
DrugBank
Sales cycle + procurement (weeks to months)
First Databank (FDB)
Sales + RFP + integration (months)
Micromedex (Merative)
Sales + procurement + integration (months)
openFDA (DIY)
Immediate data access; 3-6 months to build production system

Interaction Output

RxLabelGuard
Structured JSON: severity, mechanism, recommendation, evidence citations
DrugBank
Structured interaction pairs with categories
First Databank (FDB)
Structured monographs with severity, management, references
Micromedex (Merative)
Detailed monographs with severity + documentation quality grading
openFDA (DIY)
Raw prose text from drug label (requires your own NLP)

Evidence Citations

RxLabelGuard
SPL Set ID + label section + text snippet per interaction
DrugBank
Literature references in monographs
First Databank (FDB)
Literature references and editorial citations
Micromedex (Merative)
Literature references rated by documentation quality
openFDA (DIY)
Full label text available (no structured citations)

Drug Resolution

RxLabelGuard
RxNorm (RxCUI), NDC, brand names, generic names
DrugBank
DrugBank IDs, InChI, SMILES, UNII
First Databank (FDB)
FDB IDs, NDC, GCN, GPI codes
Micromedex (Merative)
Micromedex IDs, NDC, proprietary codes
openFDA (DIY)
RxCUI, NDC, brand/generic names (manual query construction)

Response Formats

RxLabelGuard
Three modes: structured, summary, conversational
DrugBank
JSON/XML via REST API
First Databank (FDB)
Integration via proprietary SDK or data feeds
Micromedex (Merative)
Web-based reference or proprietary integration
openFDA (DIY)
JSON (raw label fields)

Severity Scoring

RxLabelGuard
5 levels: contraindicated, major, moderate, minor, unknown
DrugBank
Severity categories (varies by product)
First Databank (FDB)
Multi-level severity with clinical significance ratings
Micromedex (Merative)
Severity + documentation quality (2-dimensional)
openFDA (DIY)
None (raw text only)

API Format

RxLabelGuard
REST API (JSON over HTTPS)
DrugBank
REST API (JSON/XML)
First Databank (FDB)
Proprietary SDK, data feeds, or AlertSpace API
Micromedex (Merative)
Web interface, proprietary integration
openFDA (DIY)
REST API (JSON over HTTPS)

Rate Limits

RxLabelGuard
10/60/240 req/min by tier (Sandbox/Developer/Professional)
DrugBank
Defined per enterprise contract
First Databank (FDB)
Defined per enterprise contract
Micromedex (Merative)
Defined per enterprise contract
openFDA (DIY)
240 req/min, 120K req/day (with free API key)

Need a more focused comparison? See our evidence-backed buyer guide or jump to a specific alternative below.

Retiring March 25, 2026

DrugBank API

DrugBank has been one of the most widely referenced drug databases in the world, with over 14,000 drug entries and extensive coverage of targets, enzymes, transporters, and carriers. Researchers, pharmaceutical companies, and clinical developers have relied on DrugBank for years to power drug-related features in their software.

However, the landscape is shifting. DrugBank announced that its free Interaction Checker tool and the DDI Checker API endpoint will be retired on March 25, 2026. Teams currently relying on this service need to evaluate alternatives before the cutoff. The full DrugBank database remains available under enterprise licensing, but the free interaction checking capability is going away.

DrugBank's data is proprietary and editorially curated. This means a team of pharmacists and researchers manually reviews and updates interaction records. The upside is high data quality and comprehensive coverage. The downside is that access requires an enterprise contract with pricing that starts in the five-figure range annually, placing it out of reach for startups, independent developers, and smaller clinical practices.

For teams that need to migrate off DrugBank's Interaction Checker, the primary considerations are: (1) whether you need the proprietary curation or can work with FDA-sourced data, (2) whether your budget supports enterprise licensing, and (3) how quickly you need to be operational on a new system.

If you are evaluating DrugBank alternatives specifically, we have a dedicated page with migration guidance, a feature-by-feature comparison, and step-by-step instructions for switching to an FDA-sourced API.

DrugBank Alternative GuideDrugBank Retirement Details

Enterprise Vendor

First Databank (FDB)

First Databank, a subsidiary of Hearst Health, is one of the longest-established clinical drug knowledge base providers in the healthcare industry. FDB MedKnowledge is integrated into the majority of hospital EHR systems in the United States and powers drug interaction checking, dosing guidance, allergy screening, and formulary management across thousands of health systems.

FDB's drug interaction module is clinically validated with a team of pharmacists and clinical editors who continuously review and update interaction monographs. The database covers drug-drug, drug-food, drug-alcohol, and drug-disease interactions with severity grading, clinical significance ratings, and detailed management recommendations. This depth of coverage is unmatched by most competitors.

The trade-off is cost and complexity. FDB is an enterprise product. Pricing typically starts at $50,000 per year and scales well into six figures depending on the number of endpoints, beds, or transactions. Procurement involves an RFP process, legal review, and a multi-month implementation timeline. There is no free tier, no self-service signup, and no public API documentation you can evaluate before engaging with sales.

For large health systems, established EHR vendors, and organizations with dedicated procurement teams, FDB is a strong choice. It has decades of track record, regulatory acceptance, and comprehensive clinical content. For startups, independent developers, and teams that need to move quickly, the barrier to entry is prohibitively high.

If your use case requires the breadth of an enterprise clinical knowledge base and your budget supports it, FDB deserves a spot on your evaluation shortlist. If you need FDA-sourced interaction data with a fast integration path and transparent pricing, consider an alternative.

First Databank Alternative GuideCompare Pricing

Enterprise Vendor

Micromedex (Merative / IBM Health)

Micromedex, now part of Merative (formerly IBM Watson Health), is one of the most recognized names in clinical drug information. Originally developed by Thomson Healthcare and later acquired by IBM, Micromedex provides a comprehensive suite of drug information resources including DRUGDEX, drug interaction checking, IV compatibility data, toxicology information, and patient education materials.

The Micromedex drug interaction database is built on a foundation of editorial review by clinical pharmacists. Interactions are graded by severity (contraindicated, major, moderate, minor) and by documentation quality (excellent, good, fair, unknown). This two-dimensional classification gives clinicians more nuanced information than a simple severity score alone. Each interaction includes a detailed monograph with mechanism, clinical effects, management recommendations, and literature references.

Micromedex has traditionally been sold as a bundled product. Health systems license access to the full Micromedex suite, which includes not just drug interactions but also drug monographs, dosing calculators, patient education handouts, and toxicology references. This bundling means that the effective cost of the drug interaction module alone is difficult to isolate. Published pricing is not available, but industry estimates place annual licensing in the $50,000 to $200,000+ range depending on institutional size and modules licensed.

The transition from IBM to Merative has introduced some uncertainty. Merative is operating as an independent company after its 2022 spin-off from IBM, and customers have reported changes in support responsiveness and product roadmap clarity during the transition. That said, the core Micromedex content remains clinically robust and widely trusted.

For organizations that need a comprehensive clinical reference library beyond just drug interactions, Micromedex delivers. For teams that specifically need a programmatic drug interaction API with modern developer ergonomics and transparent pricing, the enterprise procurement model may not be the right fit.

Micromedex Alternative GuideDrug Interaction API Overview

Free Government Data

openFDA Drug Label API (DIY Approach)

The openFDA Drug Label API provides free, unrestricted access to the full text of FDA-approved drug labels. This includes the drug_interactions section, which contains the manufacturer-reported drug interaction information for every approved medication. The data is in the public domain, requires no licensing fees, and is updated as the FDA processes label revisions.

The appeal of building directly on openFDA is clear: zero cost for data access, no vendor lock-in, and full control over your processing pipeline. For research projects, academic applications, and teams with data engineering expertise, this is a legitimate path.

The challenge is that openFDA returns raw, unstructured label text. The drug_interactions field is a block of prose written for human clinicians, not machines. To turn this into actionable structured data, you need to build several layers of infrastructure yourself:

  • Drug name resolution: Mapping brand names, generic names, misspellings, and product codes to standard identifiers. The NLM RxNorm API handles this well, but you still need to build the integration and handle edge cases.
  • NLP extraction: Parsing unstructured prose into structured interaction pairs. This requires NLP models, entity recognition, and relationship extraction. You can use LLMs like Claude or GPT-4 for this, but you need to design prompts, handle errors, and validate output.
  • Severity classification: The FDA labels do not include standardized severity grades. Words like "contraindicated," "serious," and "monitor closely" appear in prose but require clinical logic to map to consistent severity levels.
  • Cross-drug matching: To check whether Drug A interacts with Drug B, you may need to check both Drug A's label and Drug B's label, then deduplicate and reconcile any differences.
  • Caching and freshness: Labels update irregularly. You need a caching layer that serves fast responses while periodically refreshing stale data.

Realistically, building a production-ready drug interaction service on openFDA is a 3-6 month engineering effort for a skilled team. The result is a system that only you maintain, with no external support, and with clinical accuracy that depends entirely on the quality of your NLP pipeline.

We have a detailed developer guide that walks through the openFDA Drug Label API in depth, including search syntax, field mappings, rate limits, and practical examples for building on the raw data.

openFDA Developer GuideProgrammatic Interaction Checking Tutorial

Managed API Service

How RxLabelGuard Fits Into the Landscape

RxLabelGuard occupies a specific position in the drug interaction API market: it bridges the gap between free-but-unstructured government data (openFDA) and expensive-but-comprehensive enterprise knowledge bases (FDB, Micromedex, DrugBank). It is built for developers and small-to-medium organizations that need structured, evidence-cited drug interaction data without enterprise procurement cycles or six-figure annual contracts.

The core pipeline works as follows. When you send drug names to the API, RxLabelGuard resolves them to standardized RxCUI identifiers using NLM's RxNorm vocabulary. It then retrieves the current FDA-approved drug labels from openFDA, extracts interaction information using a combination of deterministic NLP and AI-powered structuring via AWS Bedrock (Claude), and returns the results as structured JSON with severity scoring, mechanism descriptions, recommendations, and evidence citations that link back to the original FDA label sections.

This approach has concrete advantages. Every interaction returned by RxLabelGuard includes the SPL Set ID (the stable identifier for the source drug label), the specific label section where the interaction was found, and a text snippet from the original FDA label. This means every alert in your clinical software can be traced back to its authoritative source. For regulatory compliance, audit trails, and clinical transparency, this matters.

What RxLabelGuard does well

  • Self-service onboarding: Create an account, generate an API key, and make your first request in minutes. No sales calls, no procurement cycles.
  • Transparent pricing: Free tier at $0/month (50 requests), Developer at $20/month (2,000 requests), Professional at $99/month (20,000 requests). No hidden fees, no per-seat licensing.
  • Multiple response formats: Structured (machine-parseable JSON), summary (concise clinical text), and conversational (natural language explanation). Choose the format that fits your UI.
  • Five-level severity scoring: Contraindicated, major, moderate, minor, and unknown. Calibrated to reduce alert fatigue while catching clinically significant interactions. See severity level documentation.
  • Flexible drug resolution: Accept drug names (brand or generic), NDC codes, or RxCUI identifiers. The API handles normalization internally.

Where to set realistic expectations

  • FDA data only: RxLabelGuard sources interaction data from FDA Structured Product Labeling. It does not include proprietary clinical monographs, drug-food interactions, IV compatibility data, or patient education materials that enterprise vendors offer.
  • Coverage differences: FDA labels may not document every interaction that curated databases include. Conversely, FDA labels may contain interaction warnings that proprietary databases omit or classify differently.
  • Newer product: RxLabelGuard is newer than established enterprise vendors. It does not yet have the decades-long track record of FDB or Micromedex.

Integration examples

RxLabelGuard is a standard REST API that accepts JSON and returns JSON. Here are working examples in three common languages.

cURL

curl -X POST https://jd6095ijga.execute-api.us-east-2.amazonaws.com/v1/interactions/check \
  -H "Content-Type: application/json" \
  -H "x-api-key: YOUR_API_KEY" \
  -d '{"drugs": ["warfarin", "aspirin"]}'

Python

import requests

response = requests.post(
    "https://jd6095ijga.execute-api.us-east-2.amazonaws.com/v1/interactions/check",
    headers={"x-api-key": "YOUR_API_KEY"},
    json={"drugs": ["warfarin", "aspirin"]}
)
data = response.json()

for interaction in data.get("interactions", []):
    print(f"{interaction['severity']}: {interaction['drug1']} + {interaction['drug2']}")
    print(f"  Mechanism: {interaction['mechanism']}")
    print(f"  Source: {interaction['evidence']['splSetId']}")

JavaScript (Node.js / Browser)

const response = await fetch(
  "https://jd6095ijga.execute-api.us-east-2.amazonaws.com/v1/interactions/check",
  {
    method: "POST",
    headers: {
      "Content-Type": "application/json",
      "x-api-key": "YOUR_API_KEY",
    },
    body: JSON.stringify({ drugs: ["warfarin", "aspirin"] }),
  }
);
const data = await response.json();

data.interactions.forEach((ix) => {
  console.log(`${ix.severity}: ${ix.drug1} + ${ix.drug2}`);
  console.log(`  Mechanism: ${ix.mechanism}`);
  console.log(`  Source: ${ix.evidence.splSetId}`);
});

The response includes structured interaction data with severity classification, mechanism of action, clinical recommendations, and full evidence citations linking back to the FDA label. This means your application can display not just "there is an interaction" but also "here is the severity, here is why, and here is the FDA source you can verify."

Create Free AccountFull API DocumentationView Pricing

Which Drug Interaction API Is Right for You?

The best choice depends on your organization's size, budget, technical capacity, data requirements, and timeline. Here are five common scenarios and the option that fits each one best.

1You need curated, editorially-maintained clinical data with monographs

If your use case requires drug-food interactions, IV compatibility, patient education materials, or detailed clinical monographs written by pharmacists, you need an enterprise clinical knowledge base. These products are expensive and require procurement cycles, but they provide the deepest clinical content available.

Best fit: DrugBank, First Databank (FDB), or Micromedex

2You need FDA-sourced evidence with traceable citations

If your compliance requirements demand that every drug interaction alert link back to an authoritative FDA source with a stable identifier, label section reference, and text snippet, you need an API that preserves this provenance chain. FDA Structured Product Labeling is public, verifiable, and independently auditable.

Best fit: RxLabelGuard

3You want full control over the extraction pipeline

If you have a data engineering team, NLP expertise, and the willingness to invest 3-6 months in building and maintaining your own drug interaction extraction system, you can build directly on openFDA. This gives you maximum flexibility but requires ongoing maintenance and clinical validation effort.

Best fit: openFDA (DIY)

4You need a free tier to prototype before committing

If you are building a proof of concept, evaluating feasibility, or bootstrapping a startup, you need to test with real data before committing budget. Only two options provide free access to drug interaction capabilities: openFDA (raw data, requires your own processing) and RxLabelGuard (structured output, 50 requests/month).

Best fit: RxLabelGuard (structured, free tier) or openFDA (raw data, unlimited)

5You need enterprise SLA, dedicated support, and regulatory pedigree

If you are a large health system, an established EHR vendor, or an organization that requires contractual SLAs, dedicated account management, 24/7 support, and a vendor with decades of regulatory track record, the enterprise vendors are the right choice despite their cost and procurement complexity.

Best fit: First Databank (FDB), Micromedex, or DrugBank

A note on clinical validation

No drug interaction API should be used as the sole basis for clinical decisions. Regardless of which API you choose, your implementation should include appropriate clinical review workflows, override documentation, and audit trails. The API is a tool that supports clinical decision-making; it does not replace clinical judgment.

Many organizations use a layered approach: a managed API like RxLabelGuard for fast, evidence-cited interaction checks in their primary workflow, with an enterprise vendor like FDB or Micromedex as a secondary reference for complex cases. This provides the best of both worlds: fast developer integration for the common case, and deep clinical content for edge cases.

Frequently Asked Questions

Common questions about drug interaction APIs, data sources, and choosing the right option.

What is a drug interaction API?

A drug interaction API is a programmatic interface that allows healthcare software to check for potential interactions between medications. You send a list of drugs (by name, NDC code, or RxCUI identifier), and the API returns structured data about known interactions including severity classifications, mechanisms of action, clinical recommendations, and source references.

These APIs are essential components of electronic health records (EHR), pharmacy management systems, telehealth prescribing workflows, and clinical decision support tools. They help prevent adverse drug events by alerting healthcare providers when a patient's medication regimen contains potentially harmful combinations.

Which drug interaction API has the best free tier?

RxLabelGuard offers a free Sandbox tier with 50 structured requests per month, including severity scoring and evidence citations. No credit card is required. This is sufficient for prototyping, feasibility testing, and low-volume development.

openFDA provides unlimited free access to raw drug label data (240 requests per minute with an API key), but the data is unstructured prose that requires your own NLP extraction, drug name normalization, severity classification, and cross-drug matching. DrugBank, First Databank, and Micromedex do not offer free tiers and require enterprise contracts.

How does FDA-sourced data compare to curated databases?

FDA Structured Product Labeling (SPL) is the authoritative source of drug interaction information for FDA-approved medications. Every approved drug must include interaction information in its label. This data is public, independently verifiable, and updated as the FDA processes label revisions.

Curated databases like DrugBank, First Databank, and Micromedex add significant value on top of FDA data: editorial review by clinical pharmacists, additional interaction pairs sourced from medical literature, standardized severity grading, and detailed clinical monographs. However, this curation is proprietary, meaning you cannot independently verify the editorial decisions.

The practical difference depends on your use case. If you need traceable, auditable interaction data from an authoritative public source, FDA-sourced APIs like RxLabelGuard provide that. If you need the broadest possible coverage including interactions sourced from journals and expert consensus, enterprise curated databases offer that at significantly higher cost.

Can I switch from DrugBank to RxLabelGuard?

Yes. RxLabelGuard accepts drug names (brand or generic), NDC codes, and RxCUI identifiers, making it straightforward to adapt existing integrations. The response format is structured JSON with severity, mechanism, recommendation, and evidence fields.

The key differences to be aware of: RxLabelGuard sources data from FDA Structured Product Labeling rather than DrugBank's proprietary curated database. Interaction coverage may differ in some cases. We recommend testing your critical drug pairs during evaluation to verify coverage for your specific use case.

We have a dedicated DrugBank migration guide with step-by-step instructions, API mapping, and a side-by-side feature comparison.

What severity levels do drug interaction APIs provide?

Most drug interaction APIs classify interactions into severity tiers to help clinical software determine which alerts to display and how prominently. RxLabelGuard uses five levels: contraindicated (drugs must not be used together), major (potentially life-threatening or may cause permanent harm), moderate (may require monitoring or dose adjustment), minor (minimal clinical significance), and unknown (insufficient data to classify).

Enterprise vendors use similar but sometimes different schemes. Micromedex adds a documentation quality dimension (excellent, good, fair, unknown) alongside severity. First Databank includes clinical significance ratings. DrugBank uses severity categories that vary by product version. openFDA provides no severity classification because it returns raw label text.

The goal of severity classification is to reduce alert fatigue. Studies show clinicians override 90% or more of drug interaction alerts when severity is poorly calibrated. Effective severity scoring helps surface critical alerts while suppressing low-value warnings.

How often is drug interaction data updated?

Update frequency varies by data source. FDA drug labels are updated as the FDA processes label revisions from manufacturers. For any given drug, this can happen at any time but is typically infrequent (months to years between revisions for established medications, more frequently for newer drugs or safety signals).

RxLabelGuard caches FDA labels and refreshes them periodically to balance response speed with data freshness. Each cached label includes its effective date so you can verify currency. Enterprise vendors like First Databank and Micromedex update their databases on monthly or quarterly editorial cycles, with urgent safety updates processed on shorter timelines.

For most clinical use cases, the difference in update frequency between these sources is not clinically significant. Major new drug interactions are typically communicated through FDA safety alerts, MedWatch notices, and Dear Healthcare Provider letters before they appear in any database.

Related Resources

Dive deeper into specific alternatives, technical guides, and integration tutorials.

DrugBank API Alternative

Migration guide for teams moving off DrugBank's retiring Interaction Checker.

Read more

First Databank Alternative

How RxLabelGuard compares to FDB for teams evaluating enterprise alternatives.

Read more

Micromedex Alternative

Comparing Micromedex's enterprise offering with managed API alternatives.

Read more

Medi-Span Alternative

How RxLabelGuard compares to Wolters Kluwer Medi-Span for drug interaction data.

Read more

openFDA Developer Guide

Technical deep dive into the openFDA Drug Label API for teams building from scratch.

Read more

Drug Interaction API Overview

Comprehensive guide to what drug interaction APIs are and how they work.

Read more

Free Drug Interaction API

How to get started with drug interaction checking at zero cost.

Read more

How to Check Interactions Programmatically

Step-by-step tutorial with code examples in Python, JavaScript, and cURL.

Read more

Severity Levels Documentation

Understanding the five severity levels and how to use them in your clinical UI.

Read more

Ready to evaluate?

Create a free account and test RxLabelGuard with your critical drug pairs. No credit card required. 50 requests per month on the free tier.

Create Free AccountView API Docs

Already have an account? Go to your dashboard

Medical Disclaimer: This information is derived from FDA Structured Product Labeling and is provided for informational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Competitor information is based on publicly available documentation as of March 2026 and may not reflect the most current product offerings.